PCV5 Thromboembolisms with Thrombopoietin Receptor Agonists: Systematic Review and Meta-Analysis of Randomized Controlled Trials  by Corrales-Álvarez, I. et al.
endogenous cost-effectiveness analysis policies aimed at lowering spending may
actually raise it. Second, reimbursement policy based on endogenous cost-effec-
tiveness levels may lead to adoption of more inefficient treatments. Under the
standard conditions when producer costs are unobservable, we provide a test for
these conditions using data on technology appraisals in the UK 1999-2005.
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THE VALUES OF GENERAL PRACTITIONERS/FAMILY PHYSICIANS SHOULD BE
FOSTERED INTO OTHER CLINICIANS: A RESEARCH STUDY
Han-You X
Clinical institute, Workers’ hospital of Nanyang textile corporation, Nanyang city , China
OBJECTIVES: The paper is to improve the quality of life and health of the peoples of
the world by fostering and maintaining high standards of care in general practice/
family medicine and other clinicians. METHODS: By comparing the general prac-
titioners/family physicians with the clinicians of specialities, summarizing the
shortcomings of present health care services, the proposals for promoting health
care services around the world were suggested. RESULTS: The article initiates that
the values of general practice/family medicine should be fostered into other clini-
cians when all the clinicians take care of the patients in any conditions, critical or
ordinary, by adopting to the values of general practice/family medicine. While the
clinicians also take into account of their own specialities. CONCLUSIONS: In ap-
plying these proposals, a healthy world and high quality of life of the peoples of the
world will come soon! So the quality of life and health of the peoples of the world
can be promoted and enhanced.
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OBJECTIVES: The main objective of this study was to understand the appropriate-
ness of a GPs Longitudinal Database on exploring potential causal associations
among therapies and adverse events. We’ve focused on subjects treated with three
of the most widespread atypical antipsychotics drugs known as affecting patients’
lipidic profile and cardiovascular and diabetes risk.METHODS:Data were obtained
from CSD LPD, an Italian General Practitioner’s longitudinal database. Patients
with a first prescriptions of Aripiprazole, Olanzapine or Quetiapine during the pe-
riod January 2005 to December 2009 have been selected. For each patient, the first
prescription has been considered as the Index Date. The final study sample was
composed of patients that during the following three months had at least another
prescription of the same atypical antipsychotic. Patients have been followed-up for
a maximum of 12 months starting from three months after the Index Date.
RESULTS: Treatment groups were composed of 367 patients for Aripiprazole, 1825
patients for Olanzapine and 3088 patients for Quetiapine. The proportion of pa-
tients with an out of range value of Total Cholesterol and LDL was significantly
lower in Aripiprazole group. The same trend has been observed for the proportion
of patients with at least one recorded diagnosis of cardiovascular events and dia-
betes. The association between treatment and cardiovascular diagnosis presence
was still significant even when performing a multivariate logistic model adjusted
for age, gender and presence of a cardiovascular diagnosis during the year before
the Index Date (Odds Ratio Olanzapine VS. Aripiprazole: 1.76 [1.08 – 2.85]; Odds
Ratio Quetiapine versus Aripiprazole: 1.67 [1.03 – 2.70]). CONCLUSIONS: CSD LPD
database resulted to be appropriate in exploring potential causal associations
among treatments and potential adverse events both in terms of recorded diagno-
sis and in terms of recorded laboratory exams values even if, in this case, the
sample size was reduced.
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OBJECTIVES: To compare the prophylaxis patterns, incidence of venous thrombo-
embolism (VTE), major and minor bleeding and readmission over 90 days in hos-
pitalized medically ill patients.METHODS:A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a health insurance claims database. Eli-
gible patients were selected if they were continuously enrolled in their health plan
for at least 180 days prior to and 90 days following the index hospital discharge, for
which they were hospitalized with a medically ill diagnosis. Prophylaxis use was
defined as receiving low molecular weight heparin (LMWH) only, warfarin only,
unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin, or
UFH and warfarin, from the index hospitalization date to 30 days after index hos-
pital discharge and before VTE events. Risk-adjusted venous thromboembolism
and major and minor bleeding events among patients with different thrombopro-
phylaxis patterns were compared. RESULTS: In patients who were identified as
medically ill (n12,077), 6,464 (53.52%) received anticoagulant therapy during their
hospitalization and until 30 days after discharge. Among these patients who re-
ceived prophylaxis, 2,137 (33.06%) received LMWH only, 693 (10.72%) received war-
farin only, 2168 (33.54%) received UFH only, 12 (0.19%) received fondaparinux only,
291 (4.50%) received LMWH and warfarin, and 325 (5.03%) received UFH and war-
farin. Among the 6 prophylaxis patterns, patients who received LMWH only were
associated with lower VTE (0.39% vs. 1.98%, p0.0001) and readmission rates (8.38%
vs. 13.68%, p0.0049) than those with LMWH and warfarin combination therapy. In
addition, the LMWH only group of patients had lower rates of major and minor
bleeding than the UFH and warfarin combination therapy group. CONCLUSIONS:
Despite existing guidelines, few medically ill patients receive anticoagulant pro-
phylaxis. Appropriate anticoagulant prophylaxis results in lower VTE event rates in
hospitalized medically ill patients.
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OBJECTIVES: To assess the real-world rate of appropriate prophylaxis use for inci-
dences of venous thromboembolism (VTE), and major and minor bleeding in hos-
pitalized medically ill patients. METHODS: A retrospective study (January 01, 2005
to December 31, 2007) was conducted using a health insurance claims database.
Eligible patients were selected if they were continuously enrolled in their health
plan for at least 180 days prior to and 30 days following the index hospital discharge
date, for which they were hospitalized with a medically ill diagnosis. Prophylaxis
use was defined as receiving low molecular weight heparin (LMWH) only, warfarin
only, unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin,
or UFH and warfarin, from the index hospitalization admission date to 30 days after
index hospital discharge, and before VTE events. Risk-adjusted VTE and major and
minor bleeding events among patients with different thromboprophylaxis pat-
terns were compared. RESULTS: In patients who were identified as medically ill
(n12,947), 6,949 (53.67%) received anticoagulant therapy during their hospitaliza-
tion and until 30 days after discharge. Among those patients who received prophy-
laxis, 2,295 (33.03%) received LMWH only, 752 (10.82%) received warfarin only, 2,313
(33.29%) received UFH only, 12 (0.17%) received fondaparinux only, 309 (4.45%)
received LMWH and warfarin, and 353 (5.08%) received UFH and warfarin. Com-
pared with patients who received LMWH only, patients who received the combi-
nation therapy of LMWH and warfarin had significantly more VTE events (1.14% vs.
0.32%, p0.0099) and higher readmission rates (6.11% vs. 3.05%, p0.0093), while
patients who received the combination therapy of UFH and warfarin had signifi-
cantly higher minor bleeding (11.70% vs. 6.06%, p0.0002) and readmission rates
(7.49% vs. 3.05%, p0.0001). CONCLUSIONS: Appropriate anticoagulant prophy-
laxis use results in lower VTE event rates as well as lower major and minor bleeding
rates in hospitalized medically ill patients. More effort is required to improve the
use of appropriate thromboprophylaxis.
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OBJECTIVES: The aim of this study was to assess whether restoration and mainte-
nance of sinus rhythm is associated with clinically meaningful improvement in
patients with atrial fibrillation (AF) or atrial flutter (AFI). METHODS: Assessment
was based on randomized controlled trials (RCTs) identified by means of system-
atic review, carried out according to the Cochrane Collaboration guidelines. Studies
met the inclusion criteria if they directly compared two treatment strategies, i.e.
maintenance of sinus rhythm (MSR) including first generation antiarrhythmic
drugs (FGAAD; mainly amiodarone, sotalol, dizopiramide, propafenone, dofetilide,
flecainide) vs. rate control (RC) including pharmacologic agents (calcium channel
blockers, beta blockers, cardiac glycosides), with regard to clinically meaningful
endpoints. The most important medical databases (EMBASE, MEDLINE and CEN-
TRAL) were searched until January 2011. Two reviewers independently selected
trials, assessed their quality and extracted data. RESULTS: Eight RCTs directly
comparing MSR vs RC were identified and included. Meta-analysis of those studies
showed that significantly more patients assigned to MSR were in sinus rhythm at
the end of study as compared to RC strategy (RB  4.49 [2.49; 8.09]; NNT13-
37months  2 [2-4]). However, it did not lead to any benefit regarding clinically
meaningful endpoints. Comparison between both treatment strategies revealed no
statistically significant difference with respect to risk of overall mortality (RR 1.06
[0.96; 1.17]), cardiovascular mortality (RR 1.01 [0.88; 1.16]), stroke (RR 1.02 [0.82;
1.26]), systemic embolism (RR 0.78 [0.35; 1.71]), heart failure (RR 0.94 [0.80; 1.09])
or bleeding (RR 1.10 [0.65; 1.84]). CONCLUSIONS: In this analysis, restoration and
maintenance of sinus rhythm achieved with FGAAD was not associated with clin-
ically meaningful improvement in patients with AF or AFl. MSR strategy neither
improved survival nor decreased morbidity as compared to RC. The reevaluation of
current criteria of antiarrhythmic drug assessment should be considered.
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OBJECTIVES: Romiplostim and eltrombopag are thrombopoietin receptor (TPOr)
agonists that promote megakaryocyte differentiation, proliferation and platelet
production. Both are orphan drugs mainly indicated for the treatment of adult
chronic idiopathic thrombocytopenic splenectomised patients who are refractory
to other treatments. Due to increasing platelet counts above the normal range may
represent a risk for thromboembolisms, we assessed whether TPOr agonists affect
thromboembolisms occurrence by a systematic review and meta-analysis of ran-
domised controlled trials (RCTs). METHODS: We searched PubMed, SCOPUS, Co-
chrane Central Register, regulatory agencies websites and publicly available regis-
tries of manufacturers (before January 2011). RCTs using romiplostim or
eltrombopag in at least one group were included. Absolute risk ratios (ARR) and
number needed to harm (NNH) were calculated to provide the population health
impact of the exposure. Relative risks (RR) were also provided. Data were pooled
using fixed-effects models. Heterogeneity was analysed using Cochran’s Q and I2
tests. RESULTS: Of 373 publications identified, 8 studies met the inclusion criteria
(n1,180 patients). In the TPOr agonist group, as compared with the control group
(e.g. placebo and/or standard of care), the meta-ARR for thromboembolisms was
1.8% (95% CI, 0.0% to 3.6%), and the meta-RR was 1.5 (95% CI, 0.7 to 3.3). Fifty-five
patients would have to be treated using TPOr agonists to produce thromboembo-
lisms in a patient (meta-NNH55). Non heterogeneity was found (Cochran’s Q test,
P  0.9; I2  0.0%). CONCLUSIONS: Although the small numbers reported, throm-
boembolisms should be considered as identified risks for these drugs. Healthcare
providers should use caution when administering these agents to patients with
known risk factors for thromboembolisms.
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OBJECTIVES: In a recent study in patients receiving warfarin, the initiation of st-
atins that are cytochrome P450 3A4 inhibitors was associated with an increased
risk of hospitalization for gastrointestinal bleeding in a Medicaid-insured popula-
tion, while the initiation of pravastatin was not. The present research attempted to
address some of the study limitations and assess whether similar findings are
applicable in a more recent, commercially-insured U.S. population. METHODS: A
retrospective matched-cohort design was used to compare baseline characteristics
and bleeding rates (e.g. gastrointestinal and non-gastrointestinal) between statin
and statin-free patients receiving warfarin concomitantly. Patients were matched
on a 1:1 ratio to balance patient characteristics, and a cox proportional hazard
model was used to control for confounding factors. The analyses were performed
for a matched “stabilized” population, i.e., patients who had been on warfarin for
6 months, did not have prior bleeding events, and did not use another statin
before the index date. For the matched “stabilized” populations, sub-group analy-
ses were performed on patients with atrial fibrillation, patients with venous throm-
bosis, patients age65 years, patients age75 years, prevalent/persistent warfarin
users, and by statin therapy. RESULTS: The method produced a small matched
sample of 6306 (3.82%) out of 123,328 statin users and 41,734 statin-free patients.
There were no statistically significant differences in bleeding rates between statin
users and statin-free patients. Results were similar for the sub-group analyses.
CONCLUSIONS: Using a claims database approach, high degree of heterogeneity
between statin users and non-users was found, resulting in a low matching rate.
This high degree of heterogeneity suggests that claims databases may be insuffi-
cient to detect/conclude as to differences in bleeding rates between statin versus
statin-free patients on warfarin. Alternative methods and additional clinical infor-
mation are needed to more accurately characterize bleeding rates in patients tak-
ing warfarin and a statin therapy concomitantly.
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OBJECTIVES: To determinate tobacco consumption effects on metabolic control
(biochemical/anthropometrics parameters), mortality and on CVE relapses inci-
dence during a 3 year follow-up. METHODS: Multicentric observational study un-
dertaken through the retrospective review of the medical records of patients at six
primary health-care centres and two hospitals. Inclusion criteria: subjects  30
years, who requested health care after suffering a CVE between 2003 and 2007.
Follow-up: 36 months. Groups: smokers, ex-smokers and non-smokers. Main mea-
sures: sociodemographics, morbidity, biochemical/anthropometrics parameters
(systolic and diastolic arterial pressure (mmHg), baseline glycaemia (mg/dL), body
mass index (kg/m2), serum triglycerides (mg/dL), total cholesterol (mg/dL), HDL-
cholesterol and LDL-cholesterol (mg/dL)), mortality and later CVE (ischemia, infarc-
tion, strokes, ischemic accident, peripheric artheriopathy). Statistical analysis: lo-
gistic regression model and Kaplan-Meier curves. RESULTS: 2,540 patients fulfilled
the inclusion criteria (smokers: 8.4%, exsmokers: 52.9%, non-smokers: 38.7%).
Mean age: 68.1 years old; men: 60.7%. By groups: patients showed a similar distri-
butions of comorbidities. 19.1% of smokers still smoked after the first CVE. Smoking
addiction was related with COPD (odds ratio, OR2.4; 95%CI: 1.7-3.5) and depres-
sive syndrome (OR1.5; 95%CI: 1.1-2.2). The smoking condition mean time was 24.4
(14.5) years for smokers and 4.2 (1.2) years for ex-smokers. Comparing baseline
(during hospitalization) and final (3 years follow-up), in the non-smokers group, all
parameters showed a significant reduction (8 to (8/8), in exsmokers (6/8) and in
smokers group only 4/8. All mortality causes (intrahospital and follow-up included)
was 4.2% (N106; 95%CI: 3.4-5.0%), in smokers: 4.2%; ex-smokers: 5.9% and non-
smokers: 1.8%; p0.001. Incidence rate of new CVE’s was 15.2% (95%CI: 13.8-16.6%)
in smokers: 18.6%; ex-smokers: 16.5%; non-smokers: 9.6%; p0.001. CVE’s were
present in 8.2%, 6.0% and 3.3% respectively, p0.05. CONCLUSIONS: In routine
medical practice, smokers compared with ex-smokers and with non-smokers still
support a high future risk of suffering CVE and higher mortality rates.
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OBJECTIVES: Syndrome of inappropriate antidiuretic hormone hypersecretion
(SIADH) is a common cause of hyponatremia contributing to 30-50% of hyponatre-
mia cases. Little is known of the influence of SIADH on healthcare resource utili-
zation. This study assessed the effect of SIADH on inpatient total and intensive care
unit (ICU) cost and length of stay (LOS), the likelihood of ICU admission, and 30-,
90-, and 180-day readmission. METHODS: The Premier hospital database was uti-
lized to identify US hospital inpatients discharged between January 1, 2007 and
June 30, 2009. Hyponatremic/SIADH patients were identified using primary or sec-
ondary ICD-9 codes (n430,731) and were matched to a control group (n430,731)
using exact matching on age, gender, provider region and 3M™ APR-DRG assign-
ment. Matching was further refined using propensity scores based on additional
patient and hospital covariates. Due to the contribution of congestive heart failure
and cirrhosis on hyponatremia development, these patients were excluded from
the analysis. The final analytic sample contained 65,973 SIADH patients and
407,874 non-hyponatremia/SIADH patients. Cost was analyzed using gamma re-
gression, LOS with negative binomial regression. ICU admission and hospital read-
mission were analyzed using multivariate logistic regression. RESULTS: In contrast
to non-SIADH patients, patients with SIADH had significantly higher total inpatient
cost (55.53%,CI52.53-58.60;p0.0001), ICU cost (38.07%;CI33.18-43.15;p.0001),
total LOS (45.11%,CI43.20-47.03;p0.0001), and ICU LOS (42.72%,CI38.36-47.23;
p0.0001). SIADH patients were significantly more likely to be admitted to the ICU
(OR2.131;p.0001), and readmitted at 30- (OR1.399;p0.0001), 90- (OR1.495;
p0.0001), and 180-days (OR1.459;p0.0001) in comparison with non-SIADH
patients. CONCLUSIONS: The presence of SIADH in hospitalized patients is signif-
icantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission, and likelihood of readmission. Words  297
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OBJECTIVES: To compare treatment and 12-month outcomes after percutaneous
coronary intervention (PCI) of acute coronary syndrome (ACS) patients with and
without diabetes mellitus (DM). METHODS: Data were from APTOR, robust, pro-
spective, observational registries of 14 European countries from 2007-2009. Kaplan-
Meier (KM) estimates 12-months post-PCI were calculated for cardiovascular (CV)
event (unstable angina [UA], non-ST-elevation myocardial infarction [NSTEMI],
STEMI, urgent target vessel revascularization, acute heart failure, ischemic and
hemorrhagic strokes or CV death), bleeding, and mortality. RESULTS:A total of 21%
(N942) of patients had DM (median age: 66yrs) and 79% (N3603) did not have DM
(median age: 61 yrs). More patients with DM tended to be women (28% vs. 20%);
have hyperlipidaemia (64% vs. 47%) and hypertension (75% vs. 53%); and have prior
MI (28% vs. 18%) or PCI (27% vs. 16%) compared to patients without DM. For DM/
non-DM patients respectively, ACS presentation was 29%/21% with UA, 35%/30%
with NSTEMI, 36%/49% with STEMI; the use of glycoprotein IIb/IIIa inhibitors was
28%/33% and the use of 1 drug-eluting stent (DES) was 52%/39%. DM/non-DM
patients received similar treatment at hospital discharge and 12-months post-PCI
with the exception of ARB/ACE inhibitors at discharge (75% vs. 69%) and 12-months
post-PCI (79% vs. 71%). The respective DM/non-DM 12-month outcomes were 17.3%
(95% CI: 14.8-19.7%) vs. 13.8% (12.7-15.0%) for CV event, 3.0% (1.9-4.1%) vs. 2.7%
(2.2-3.2%) for bleeding, and 4.9% (3.5-6.3%) vs. 1.8% (1.4-2.3%) for mortality. Optimal
therapy (5 of the following at hospital discharge and at one-year post-PCI: aspirin,
clopidogrel, statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet) was
observed with 49%/42% of DM/non-DM patients. CONCLUSIONS: Patients with DM
more often received DES and ARB/ACE but still incur worse 12 month outcomes
compared to non-DM. Evidence-based prescribing post ACS-PCI is still sub-optimal
and newer more potent strategies should be considered for diabetic patients to
reduce the cardiovascular mortality and morbidity disparity.
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